SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HGSI
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: 249443 who started this subject10/25/2001 4:47:16 PM
From: opalapril   of 56
 
A reminder (excerpt).
Fusion protein technology.

Principia's mission is to develop and commercialize therapeutically enhanced biopharmaceutical products offering reductions in dosage, injection frequency and side effects.

Using Principia's expertise in molecular engineering and biopharmaceutical production, Principia intends to create, develop and manufacture novel long-circulating versions of therapeutic proteins that can maintain effective but non-toxic blood levels for extended periods of time.

The technology consists of fusing albumin DNA with the DNA for a therapeutic protein or peptide. This fused DNA then signals to produce the albumin fusion protein which is manufactured using our proprietary yeast expression systems.

Delivery of protein therapeutics in a manner that is both safe and cost-effective has been a major industry challenge. Most biopharmaceuticals are injected to avoid rapid degradation in the digestive tract. However, most injected proteins are also rapidly cleared from the blood. Therefore, relatively high doses and/or frequent injections are typically needed to maintain therapeutic blood levels, resulting in potentially increased adverse side effects and increased treatment costs as well as significant patient inconvenience and non-compliance.

Principia’s albumin fusion technology may allow re-engineering of existing recombinant protein therapeutics to address the above issues. In addition, new proteins discovered by HGS are expected to benefit from the enhanced performance and cost-effectiveness provided by Principia’s albumin fusion protein technology.

(etc. etc.)
hgsi.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News